Jonathan C. Kagan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jonathan C. Kagan has a total of 418 co-authors. Here are the top co-authors by number of shared publications:
- Hao Wu
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
10 shared publications Pascal Devant
Division of Gastroenterology, Boston Children’s Hospital, Harvard Medical School
10 shared publicationsYunhao Tan
Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA
8 shared publications- Charles L. Evavold
Ragon Institute of MGH, MIT and Harvard
6 shared publications Charlotte Odendall
Department of Infectious Diseases, King's College London, London SE1 9RT, UK
6 shared publicationsDania Zhivaki
Corner Therapeutics
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Nature
NRF2 is a mechanosensitive checkpoint for NLRP3 inflammasome activation
Disconnects between in vitro and in vivo results in experimental biology have long been recognized as potential hurdles to understanding health and disease. A prototypical example of such a disconnect is the NLRP3 inflammasome, which mediates inflammation in diverse settings of disease and protective immunity1,2. Activation of the NLRP3 inflammasome in vitro requires two signals: (1) priming by pathogen-associated molecular patterns such as bacterial lipopolysaccharides and (2) activation by molecules that disrupt cellular homeostasis1,3. By contrast, the NLRP3 inflammasome in vivo is activated by lipopolysaccharide alone. The mechanisms that underlie the difference between in vitro and in vivo activation of the NLRP3 inflammasome are undefined. Here we report that extracellular matrix (ECM) stiffness is a determinant of NLRP3 activities and that in vitro systems using physiological ECM stiffness enable one-signal in vivo-like NLRP3 activities to occur in human and mouse phagocytes. Physiological ECM stiffness induced expression of the transcription factor NRF2, which was found to be necessary for one-signal NLRP3 activation. Mechanistically, we identify Panx1 as an NRF2-regulated gene that promotes NLRP3 activity. Macrophages derived from the stiff matrix of the bone-osteoclasts-had reduced NRF2 levels and impaired NLRP3 activity. Moreover, alveolar macrophages from patients with pulmonary fibrosis displayed reduced NRF2 activity. Finally, NRF2 was required for antitumour immunity induced by cancer vaccines consisting of NLRP3 agonistic adjuvants. These findings indicate that NRF2 may be a transcriptional checkpoint that controls NLRP3 inflammasome activity.
- 11 November 2026
- Published by Springer Nature in Nature
Open AccessNRF2 is a mechanosensitive checkpoint for NLRP3 inflammasome activation
Disconnects between in vitro and in vivo results in experimental biology have long been recognized as potential hurdles to understanding health and disease. A prototypical example of such a disconnect is the NLRP3 inflammasome, which mediates inflammation in diverse settings of disease and protective immunity1,2. Activation of the NLRP3 inflammasome in vitro requires two signals: (1) priming by pathogen-associated molecular patterns such as bacterial lipopolysaccharides and (2) activation by molecules that disrupt cellular homeostasis1,3. By contrast, the NLRP3 inflammasome in vivo is activated by lipopolysaccharide alone. The mechanisms that underlie the difference between in vitro and in vivo activation of the NLRP3 inflammasome are undefined. Here we report that extracellular matrix (ECM) stiffness is a determinant of NLRP3 activities and that in vitro systems using physiological ECM stiffness enable one-signal in vivo-like NLRP3 activities to occur in human and mouse phagocytes. Physiological ECM stiffness induced expression of the transcription factor NRF2, which was found to be necessary for one-signal NLRP3 activation. Mechanistically, we identify Panx1 as an NRF2-regulated gene that promotes NLRP3 activity. Macrophages derived from the stiff matrix of the bone-osteoclasts-had reduced NRF2 levels and impaired NLRP3 activity. Moreover, alveolar macrophages from patients with pulmonary fibrosis displayed reduced NRF2 activity. Finally, NRF2 was required for antitumour immunity induced by cancer vaccines consisting of NLRP3 agonistic adjuvants. These findings indicate that NRF2 may be a transcriptional checkpoint that controls NLRP3 inflammasome activity.
- Open Access
- 23 September 2026
- Published by Springer Nature in Nature
- p. 1-12
TRAM promotes Toll-like-receptor-free myddosome signal transduction
In the Toll-like receptor (TLR) signal transduction pathways, activated receptors are present for mere minutes within the initial, membrane-proximal signalling complexes called proto-myddosomes1. Proto-myddosomes are rapidly released from TLRs to self-assemble (that is, mature) into enzyme-rich, cytosolic supramolecular organizing centres called myddosomes2,3,4. Myddosomes induce hours-long inflammatory gene expression5,6,7,8,9,10. The mechanism controlling proto-myddosome release and its effect on signal transduction are undefined. Here we identify factors that regulate the maturation process of proto-myddosomes into receptor-free cytosolic myddosomes11. Through a genetic screen in macrophages, we identify TRAM, which was previously described to control MyD88-independent TLR signalling, as a regulator of myddosome assembly. Using biochemistry, live-cell imaging and activity reconstitution with recombinant proteins, we show that the plasma-membrane-associated adapter TIRAP seeds proto-myddosomes12,13, after which TRAM dissociates MyD88 from the TLR–TIRAP complex to enable myddosome maturation and downstream signal transduction14,15,16,17,18,19. In the absence of TRAM, MyD88 cannot dissociate from the TLR–TIRAP complex, resulting in abnormal and unstable MyD88 interactions with downstream signalling enzymes. These findings enabled us to identify TRAM-dependent long-lasting myddosome activities as the determinant of two TLR pathway hallmarks: hours-long NF-κB activation20,21,22,23,24 and secondary response gene expression25,26,27. Chemical dissociation of cytosolic myddosomes disrupted existing inflammatory activities of TLR-stimulated cells in vitro and in vivo. Collectively, this work establishes TRAM as a regulator of myddosome maturation and signalling, providing the molecular basis for receptor-free signal transduction.
- 23 September 2026
- Published by Springer Nature in Nature
- p. 1-12
Open AccessTRAM promotes Toll-like-receptor-free myddosome signal transduction
In the Toll-like receptor (TLR) signal transduction pathways, activated receptors are present for mere minutes within the initial, membrane-proximal signalling complexes called proto-myddosomes1. Proto-myddosomes are rapidly released from TLRs to self-assemble (that is, mature) into enzyme-rich, cytosolic supramolecular organizing centres called myddosomes2,3,4. Myddosomes induce hours-long inflammatory gene expression5,6,7,8,9,10. The mechanism controlling proto-myddosome release and its effect on signal transduction are undefined. Here we identify factors that regulate the maturation process of proto-myddosomes into receptor-free cytosolic myddosomes11. Through a genetic screen in macrophages, we identify TRAM, which was previously described to control MyD88-independent TLR signalling, as a regulator of myddosome assembly. Using biochemistry, live-cell imaging and activity reconstitution with recombinant proteins, we show that the plasma-membrane-associated adapter TIRAP seeds proto-myddosomes12,13, after which TRAM dissociates MyD88 from the TLR–TIRAP complex to enable myddosome maturation and downstream signal transduction14,15,16,17,18,19. In the absence of TRAM, MyD88 cannot dissociate from the TLR–TIRAP complex, resulting in abnormal and unstable MyD88 interactions with downstream signalling enzymes. These findings enabled us to identify TRAM-dependent long-lasting myddosome activities as the determinant of two TLR pathway hallmarks: hours-long NF-κB activation20,21,22,23,24 and secondary response gene expression25,26,27. Chemical dissociation of cytosolic myddosomes disrupted existing inflammatory activities of TLR-stimulated cells in vitro and in vivo. Collectively, this work establishes TRAM as a regulator of myddosome maturation and signalling, providing the molecular basis for receptor-free signal transduction.
- Open Access
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8137) , 1015-1024
Functional chimeric mRNAs encode proteins in mammalian immunity
Individual mammalian mRNAs and proteins are typically believed to originate from single genomic loci, with isoform diversity arising through cis -splicing of pre-mRNA. Whether mRNA from distant genes can undergo trans -splicing to generate functionally relevant chimeric transcripts has remained unclear. Here we develop a pipeline combining long-read direct RNA sequencing with non-targeted and targeted validation to identify chimeric transcripts in macrophages. Chromatin conformation capture studies reveal that inflammation induces interchromosomal DNA interactions, positioning parent genes proximally to facilitate the formation of chimeric mRNA. Notably, we identify a protein-coding chimeric mRNA representing a fusion between the pore-forming protein gasdermin D (GSDMD) 1,2 and a C-terminal domain translated out of frame from Tmem106a ( Gsdmd - Tmem106a ) in mice. We show that inflammasome priming upregulates Gsdmd - Tmem106a , with the protein localizing to the plasma membrane. After activation of the inflammasome, GSDMD–TMEM106A directly interacts with canonical GSDMD N termini to accelerate and enhance pore formation and IL-1β release. Finally, we show that GSDMD–TMEM106A balances host defence and immunopathology in vivo: its loss protects against lethal sepsis but compromises antibacterial defence, whereas overexpression enhances host protection while increasing sepsis lethality. We establish that protein-coding chimeric mRNAs formed by regulated transcript fusion events are operative during inflammation and immunity.
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8137) , 1015-1024
Open AccessFunctional chimeric mRNAs encode proteins in mammalian immunity
Individual mammalian mRNAs and proteins are typically believed to originate from single genomic loci, with isoform diversity arising through cis -splicing of pre-mRNA. Whether mRNA from distant genes can undergo trans -splicing to generate functionally relevant chimeric transcripts has remained unclear. Here we develop a pipeline combining long-read direct RNA sequencing with non-targeted and targeted validation to identify chimeric transcripts in macrophages. Chromatin conformation capture studies reveal that inflammation induces interchromosomal DNA interactions, positioning parent genes proximally to facilitate the formation of chimeric mRNA. Notably, we identify a protein-coding chimeric mRNA representing a fusion between the pore-forming protein gasdermin D (GSDMD) 1,2 and a C-terminal domain translated out of frame from Tmem106a ( Gsdmd - Tmem106a ) in mice. We show that inflammasome priming upregulates Gsdmd - Tmem106a , with the protein localizing to the plasma membrane. After activation of the inflammasome, GSDMD–TMEM106A directly interacts with canonical GSDMD N termini to accelerate and enhance pore formation and IL-1β release. Finally, we show that GSDMD–TMEM106A balances host defence and immunopathology in vivo: its loss protects against lethal sepsis but compromises antibacterial defence, whereas overexpression enhances host protection while increasing sepsis lethality. We establish that protein-coding chimeric mRNAs formed by regulated transcript fusion events are operative during inflammation and immunity.
- 27 July 2026
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 26 (10) , 818-829
Igniting antitumour immunity with cancer cell pyroptosis
- 27 July 2026
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 26 (10) , 818-829
Igniting antitumour immunity with cancer cell pyroptosis
- Open Access
- 5 December 2025
- Published by Wiley in The FEBS Journal
- Vol. 293 (7) , 2086-2097
MAVS oligomerization drives a faster and more efficient antiviral signaling activation at peroxisomes compared to mitochondria
Peroxisomes and mitochondria are important platforms for antiviral signal transduction, as detection of cytosolic viral RNA by retinoic acid‐inducible gene I (RIG‐I)‐like receptors (RLRs) induces the activation of the mitochondrial antiviral signaling adaptor (MAVS) at both organelles. To decisively elucidate the mechanistic differences and similarities in kinetics and end products between these two pathways, we developed a doxycycline‐inducible system that allows for precise control of MAVS expression and activation at either peroxisomes or mitochondria, in a timely manner, and across various cell types. Our findings demonstrate that both peroxisomal and mitochondrial MAVS induce type I and III interferon‐dependent antiviral signaling and that the peroxisomal signaling occurs significantly faster than its mitochondrial counterpart. Importantly, using not only the doxycycline‐inducible system but also the conventional activation of the MAVS pathway through direct stimulation of RIG‐I‐like receptors, we demonstrate that the rapid and robust antiviral response resulting from peroxisomal MAVS activation is mechanistically due to the faster oligomerization of MAVS at the membranes of this organelle, when compared to mitochondria. These data emphasize the versatility and speed of the peroxisome‐dependent antiviral response and may lead to the identification of specific targets to develop novel host‐directed antiviral strategies.
- 5 December 2025
- Published by Wiley in The FEBS Journal
- Vol. 293 (7) , 2086-2097
Open AccessMAVS oligomerization drives a faster and more efficient antiviral signaling activation at peroxisomes compared to mitochondria
Peroxisomes and mitochondria are important platforms for antiviral signal transduction, as detection of cytosolic viral RNA by retinoic acid‐inducible gene I (RIG‐I)‐like receptors (RLRs) induces the activation of the mitochondrial antiviral signaling adaptor (MAVS) at both organelles. To decisively elucidate the mechanistic differences and similarities in kinetics and end products between these two pathways, we developed a doxycycline‐inducible system that allows for precise control of MAVS expression and activation at either peroxisomes or mitochondria, in a timely manner, and across various cell types. Our findings demonstrate that both peroxisomal and mitochondrial MAVS induce type I and III interferon‐dependent antiviral signaling and that the peroxisomal signaling occurs significantly faster than its mitochondrial counterpart. Importantly, using not only the doxycycline‐inducible system but also the conventional activation of the MAVS pathway through direct stimulation of RIG‐I‐like receptors, we demonstrate that the rapid and robust antiviral response resulting from peroxisomal MAVS activation is mechanistically due to the faster oligomerization of MAVS at the membranes of this organelle, when compared to mitochondria. These data emphasize the versatility and speed of the peroxisome‐dependent antiviral response and may lead to the identification of specific targets to develop novel host‐directed antiviral strategies.
- Open Access
- 8 October 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (10) , e0234325
An NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates
Dendritic cells (DCs) are the primary inducers of immunity induced by infection or vaccination. To stimulate durable T cell-mediated immunity, multiple DC activities are required. DCs must present antigen, express costimulatory molecules, and secrete inflammatory cytokines to direct T cell activation. These activities must be coordinated with DC migration to the lymph node and production of memory T cell-inducing cytokines, such as IL-1β. Common vaccination approaches use adjuvants that stimulate a subset of these activities, leading to diminished T cell activities and poor immune durability. We describe herein a lipid-based adjuvant, called a hyperactivator, which elicits all five of the aforementioned DC activities. Other adjuvants examined, including those used clinically, were defective for one or more of the key activities needed for robust T cell activation. Vaccines in mice and nonhuman primates targeting influenza virus antigens, including the quadrivalent commercial product Afluria, displayed enhanced adaptive immune responses when administered using hyperactivators as adjuvants. These data highlight the impact of hyperactivator adjuvants as a means to enhance antigen-specific immunity, with potential applications towards a universal influenza vaccine. IMPORTANCE: The generation of vaccines that stimulate T cell activities is an unmet need for the scientific community, as T cells are the primary mediators of immune memory. In this study, we report a new vaccine adjuvant called a hyperactivator. This hyperactivator adjuvant diversifies the T cell and antibody responses to virus antigens, such that in nonhuman primates, all influenza strains in the clinical vaccine Afluria are targeted. Hyperactivator adjuvants may represent a means to achieve the long-sought-after goal of a universal influenza vaccine.
- 8 October 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (10) , e0234325
Open AccessAn NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates
Dendritic cells (DCs) are the primary inducers of immunity induced by infection or vaccination. To stimulate durable T cell-mediated immunity, multiple DC activities are required. DCs must present antigen, express costimulatory molecules, and secrete inflammatory cytokines to direct T cell activation. These activities must be coordinated with DC migration to the lymph node and production of memory T cell-inducing cytokines, such as IL-1β. Common vaccination approaches use adjuvants that stimulate a subset of these activities, leading to diminished T cell activities and poor immune durability. We describe herein a lipid-based adjuvant, called a hyperactivator, which elicits all five of the aforementioned DC activities. Other adjuvants examined, including those used clinically, were defective for one or more of the key activities needed for robust T cell activation. Vaccines in mice and nonhuman primates targeting influenza virus antigens, including the quadrivalent commercial product Afluria, displayed enhanced adaptive immune responses when administered using hyperactivators as adjuvants. These data highlight the impact of hyperactivator adjuvants as a means to enhance antigen-specific immunity, with potential applications towards a universal influenza vaccine. IMPORTANCE: The generation of vaccines that stimulate T cell activities is an unmet need for the scientific community, as T cells are the primary mediators of immune memory. In this study, we report a new vaccine adjuvant called a hyperactivator. This hyperactivator adjuvant diversifies the T cell and antibody responses to virus antigens, such that in nonhuman primates, all influenza strains in the clinical vaccine Afluria are targeted. Hyperactivator adjuvants may represent a means to achieve the long-sought-after goal of a universal influenza vaccine.
- Open Access
Wall teichoic acid is required for DNA-triggered innate immune receptor activation by Staphylococcus aureus
Receptors that stimulate inflammation are commonly activated by ligands that are buried within microbial cells. The mechanisms that facilitate immunostimulatory ligand release from microbes during infection are largely undefined. Using the pathogen Staphylococcus aureus , we describe wall teichoic acid (WTA) as a critical mediator of DNA release from bacterial cells during infection. Mechanistically, we found that the α-glycosylated form of WTA, generated by the enzyme TarM, is the primary mediator of bacterial DNA release within macrophages. This process is antagonized by the enzyme O-acetyltransferase, which prevents WTA attachment to peptidoglycan. This competition among peptidoglycan modifying enzymes determines activation of cytosolic DNA receptors AIM2 and cGAS. WTA therefore operates as a meta-regulator of inflammation, by controlling the availability of microbial ligands that stimulate innate immunity.
Open AccessWall teichoic acid is required for DNA-triggered innate immune receptor activation by Staphylococcus aureus
Receptors that stimulate inflammation are commonly activated by ligands that are buried within microbial cells. The mechanisms that facilitate immunostimulatory ligand release from microbes during infection are largely undefined. Using the pathogen Staphylococcus aureus , we describe wall teichoic acid (WTA) as a critical mediator of DNA release from bacterial cells during infection. Mechanistically, we found that the α-glycosylated form of WTA, generated by the enzyme TarM, is the primary mediator of bacterial DNA release within macrophages. This process is antagonized by the enzyme O-acetyltransferase, which prevents WTA attachment to peptidoglycan. This competition among peptidoglycan modifying enzymes determines activation of cytosolic DNA receptors AIM2 and cGAS. WTA therefore operates as a meta-regulator of inflammation, by controlling the availability of microbial ligands that stimulate innate immunity.
- 18 September 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (10) , 1854-1858
Towards a molecular and structural definition of cell death
- 18 September 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (10) , 1854-1858
Towards a molecular and structural definition of cell death
- Open Access
- 30 July 2025
- Published by The Royal Society in Open Biology
- Vol. 15 (7) , 240391
Oxidized phospholipid damage signals as modulators of immunity
Damage-associated molecular patterns (DAMPs) are self-derived molecules released during tissue damage that influence immune responses. Phospholipids, essential to cell membranes and lung surfactants, become oxidized under conditions of cellular stress, forming oxidized phospholipids. Unlike their unoxidized counterparts, oxidized phospholipids function as DAMPs and engage pattern recognition receptors (PRRs) on innate immune cells, activating signalling pathways that regulate immune responses. This activity alters innate immune cells, which in turn modulate the adaptive immune response, ultimately contributing to the pathogenesis of disease. Traditionally considered pro-inflammatory, recent studies reveal a more nuanced role for these lipids, with their effects on immune cells being context dependent. This review examines the mechanisms behind the generation of oxidized phospholipids and their induction in disease. We focus on recent studies that clarify how these lipids affect innate immune cells, leading to downstream effects on adaptive immunity, as well as their direct influence on adaptive immune cells. Finally, we explore therapeutic strategies targeting oxidized phospholipids to regulate immunity, offering insights into their broader role in immune regulation and potential applications in disease prevention.
- 30 July 2025
- Published by The Royal Society in Open Biology
- Vol. 15 (7) , 240391
Open AccessOxidized phospholipid damage signals as modulators of immunity
Damage-associated molecular patterns (DAMPs) are self-derived molecules released during tissue damage that influence immune responses. Phospholipids, essential to cell membranes and lung surfactants, become oxidized under conditions of cellular stress, forming oxidized phospholipids. Unlike their unoxidized counterparts, oxidized phospholipids function as DAMPs and engage pattern recognition receptors (PRRs) on innate immune cells, activating signalling pathways that regulate immune responses. This activity alters innate immune cells, which in turn modulate the adaptive immune response, ultimately contributing to the pathogenesis of disease. Traditionally considered pro-inflammatory, recent studies reveal a more nuanced role for these lipids, with their effects on immune cells being context dependent. This review examines the mechanisms behind the generation of oxidized phospholipids and their induction in disease. We focus on recent studies that clarify how these lipids affect innate immune cells, leading to downstream effects on adaptive immunity, as well as their direct influence on adaptive immune cells. Finally, we explore therapeutic strategies targeting oxidized phospholipids to regulate immunity, offering insights into their broader role in immune regulation and potential applications in disease prevention.